Skip to main content

Table 2 Procedural and Clinical Outcomes

From: Safety and efficacy of transaxillary transcatheter aortic valve replacement using a current-generation balloon-expandable valve

Variable TF (n = 100) TAx (n = 24) TT (n = 20) p Value
VARC-2 outcomes
 Device success 98 (98) 23 (95.8) 19 (95) 0.683
 Bleeding 5 (5) 1 (4.2) 0 (0) 0.593
  Life-threatening bleeding 0 (0) 0 (0) 0 (0)
  Major bleeding 3 (3) 0 (0) 0 (0) 0.510
  Minor bleeding 2 (2) 1 (4.2) 0 (0) 0.625
 Vascular complication 6 (6) 1 (4.2) 1 (5) 0.933
  Major 3 (3) 1 (4.2) 1 (5) 0.887
  Minor 3 (3) 0 (0) 0 (0) 0.510
 Cerebrovascular accident 2 (2) 0 (0) 1 (5) 0.510
 Coronary artery obstruction 0 (0) 0 (0) 0 (0)
 Pacemaker insertiona 8/89 (8.9) 4 (16.7) 5 (25) 0.125
 Paravalvular leak (<moderate) 100 (100) 24 (100) 20 (100) 1.000
 Acute kidney injuryb 5/98 (5.1) 3/23 (13.0) 4/17 (23.5) 0.032
  Stage 1 3 (3) 2 (8.3) 3 (15) 0.048
  Stage 2 2 (2) 1 (4.2) 1 (5) 0.617
 30-day Mortality 2 (2) 0 (0) 1 (5) 0.510
Other outcomes
 Transfusion 5 (5) 0 (0) 2 (10) 0.305
 New-onset atrial fibrillationc 3/65 (4.6) 1/18 (5.6) 5/15 (33.3) 0.002
 Postoperative NYHA III/IV 9 (9) 2 (8.3) 2 (10) 0.982
 Mean gradient, mmHg 10.2 ± 4.4 8.7 ± 3.2 9.2 ± 3.6 0.187
 Discharge to rehabilitation 14 (14) 4 (16.7) 7 (35) 0.077
 30-day readmission 8 (8) 2 (8.3) 7 (35) 0.002
  1. Patients with permanent pacemakera, end-stage renal diseaseb, or atrial fibrillationc at baseline are excluded
  2. Values are mean ± SD or n (%)
  3. NYHA New York Heart Association classification, PPM permanent pacemaker, TAx transaxillary, TF transfemoral, TT transthoracic, VARC Valve Academic Research Consortium